GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Century Therapeutics Inc (NAS:IPSC) » Definitions » PB Ratio

IPSC (Century Therapeutics) PB Ratio : 0.54 (As of Dec. 12, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Century Therapeutics PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-12-12), Century Therapeutics's share price is $1.25. Century Therapeutics's Book Value per Share for the quarter that ended in Sep. 2024 was $2.31. Hence, Century Therapeutics's PB Ratio of today is 0.54.

The historical rank and industry rank for Century Therapeutics's PB Ratio or its related term are showing as below:

IPSC' s PB Ratio Range Over the Past 10 Years
Min: 0.35   Med: 0.93   Max: 1.96
Current: 0.54

During the past 5 years, Century Therapeutics's highest PB Ratio was 1.96. The lowest was 0.35. And the median was 0.93.

IPSC's PB Ratio is ranked better than
91.79% of 1279 companies
in the Biotechnology industry
Industry Median: 2.52 vs IPSC: 0.54

During the past 12 months, Century Therapeutics's average Book Value Per Share Growth Rate was -37.30% per year.

Back to Basics: PB Ratio


Century Therapeutics PB Ratio Historical Data

The historical data trend for Century Therapeutics's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Century Therapeutics PB Ratio Chart

Century Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
PB Ratio
- - 2.20 0.99 1.08

Century Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.54 1.08 1.52 0.97 0.74

Competitive Comparison of Century Therapeutics's PB Ratio

For the Biotechnology subindustry, Century Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Century Therapeutics's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Century Therapeutics's PB Ratio distribution charts can be found below:

* The bar in red indicates where Century Therapeutics's PB Ratio falls into.



Century Therapeutics PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Century Therapeutics's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Sep. 2024)
=1.25/2.309
=0.54

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Century Therapeutics  (NAS:IPSC) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Century Therapeutics PB Ratio Related Terms

Thank you for viewing the detailed overview of Century Therapeutics's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Century Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
25 N 38th Street, 11th Floor, Philadelphia, PA, USA, 19104
Century Therapeutics Inc is a biotechnology company specializes in leveraging adult stem cells to develop advanced cell therapy products targeting cancer, autoimmune, and inflammatory diseases. Their innovative approach involves a genetically engineered allogeneic cell therapy platform comprising induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and cutting-edge manufacturing capabilities. This comprehensive platform aims to overcome the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and minimizing development and supply risks.
Executives
Adrienne Farid officer: Chief Operations Officer C/O CENTURY THERAPEUTICS, INC., 3675 MARKET STREET, PHILADELPHIA PA 19104
Douglas Carr officer: VP of Finance and Operations C/O CENTURY THERAPEUTICS, INC., 3675 MARKET STREET, PHILADELPHIA PA 19104
Daphne Quimi director C/O AMICUS THERAPEUTICS, INC., 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512
Gregory Russotti officer: Chief Technology Officer C/O CENTURY THERAPEUTICS, INC., 3675 MARKET STREET, PHILADELPHIA PA 19104
Luis Borges officer: Chief Scientific Officer TWO CORPORATE DRIVE, C/O FIVE PRIME THERAPEUTICS, INC., SOUTH SAN FRANCISCO CA 94080
Timothy P Walbert director 1033 SKOKIE BOULEVARD, SUITE 355, NORTHBROOK IL 60062
Versant Venture Capital Vi, L.p. 10 percent owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Joseph Jimenez director ADITUM BIO, 1111 BROADWAY, STE. 1300, OAKLAND CA 94607
Eli Casdin director 1350 AVENUE OF THE AMERICAS, SUITE 1140, NEW YORK NY 10019
Cynthia M Butitta director 3165 PORTER DRIVE, PALO ALTO CA 94304
Kimberly Blackwell director C/O ZENTALIS PHARMACEUTICALS, LLC, 530 SEVENTH AVENUE, SUITE 2201, NEW YORK NY 10018
Rizzuto Carlo director ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Alessandro Riva director C/O CENTURY THERAPEUTICS, INC., 3675 MARKET STREET, PHILADELPHIA PA 19104
Hyam Levitsky officer: President of R&D C/O ANTIGENICS INC., 162 FIFTH AVE., SUITE 900, NEW YORK NY 10010
Osvaldo Flores officer: Chief Executive Officer C/O CENTURY THERAPEUTICS, INC., 3675 MARKET STREET, PHILADELPHIA PA 19104